Retrospective Descriptive Study of Platelet Transfusion in Patients With Palliative Hematologic Malignancies at the University Hospital of Besançon

Palliative Care Clinical Trial

Official title:

Etude Descriptive Retrospective de la Transfusion Plaquettaire Chez Des Patients Atteints d'hémopathie Maligne en Phase Palliative et Suivis au CHU de Besançon

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03814486
• Other study ID #: J Moracchini
• Status: Completed
• Start date: July 1, 2017
• Est. completion date: July 1, 2018

Study information

• Verified date: December 2018
• Source: Centre Hospitalier Universitaire de Besancon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Development of palliative care is less effective for patients with hematologic malignancies. Limited data is available for end of life care in this population, moreover with thrombocytopenic patients. Thrombopenia is a frequent complication, specific of bone marrow involvement in those diseases or its treatments. Yet, a few studies was interested in, whereas platelet transfusion is the only treatment indicated. As it represent a scarce, limited resource, the ethical principles are in conflict in this setting.

The purpose of this study was to describe retrospectively platelet transfusion in the six last few month of life of patients with hematologic malignancies at the CHU of Besançon (France) between 01/07/15 and 31/12/16.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 119
• Est. completion date: July 1, 2018
• Est. primary completion date: July 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patient with hematological malignancies

• transfused in platelet at least once in the last 6 months of life

• hospitalised or follow up at the CHU of Besancon at least once

• dead during the period of the study

Exclusion Criteria:

• patient with other oncologic malignancies

• not transfused in platelet in the last 6 months of life

• never hospitalised or follow up at the CHU of Besancon

• alive

Related Conditions & MeSH terms

• Palliative Care
• Platelet Transfusion

Intervention

Other:
• descriptive
evaluate in number and efficacy platelet transfusion at the end of life, demographic characteristic are also noted

Locations

Country	Name	City	State
France	Moracchini	Besançon

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Besancon

Country where clinical trial is conducted

France, 

References & Publications (6)

Boggs DR. Jehovah's Witnesses with leukemia. Hosp Pract (Off Ed). 1985 Mar 15;20(3):92, 94-5, 98 passim. — View Citation

Höchsmann B, Moicean A, Risitano A, Ljungman P, Schrezenmeier H. Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant. 2013 Feb;48(2):168-73. doi: 10.1038/bmt.2012.220. Epub 2012 Dec 3. Review. — View Citation

Lassauniere JM, Bertolino M, Hunault M, Zittoun R, Verspieren P, Moh-Klaren J, Jaulmes D, Colombat P. Platelet transfusions in advanced hematological malignancies: a position paper. J Palliat Care. 1996 Spring;12(1):38-41. — View Citation

Salacz ME, Lankiewicz MW, Weissman DE. Management of thrombocytopenia in bone marrow failure: a review. J Palliat Med. 2007 Feb;10(1):236-44. Review. — View Citation

Sherbeck JP, Boss RD. Ethical Questions about Platelet Transfusions at the End of Life. AMA J Ethics. 2016 Aug 1;18(8):764-70. doi: 10.1001/journalofethics.2016.18.8.ecas1-1608. — View Citation

Wang WS, Ma JD, Nelson SH, Revta C, Buckholz GT, Mulroney C, Roeland EJ. Transfusion practices at end of life for hematopoietic stem cell transplant patients. Support Care Cancer. 2018 Jun;26(6):1927-1931. doi: 10.1007/s00520-017-4023-y. Epub 2017 Dec 28. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	evaluate frequency of platelet transfusion at the end of life	to calculate the number of platelet transfusion at the end of life. The number of platelet transfusion between 6 months and death are collected in each periods of 2 weeks to calculate the number of transfusion per patient during each 2 weeks.	18 months (between 07/01/2015 and 12/31/2016)
Primary	evaluate efficacy of prophylactic platelet transfusion at the end of life	to calculate the platelet yield in percentage	18 months (between 07/01/2015 and 12/31/2016)
Primary	evaluate efficacy of non prophylactic platelet transfusion at the end of life	to calculate the transfusional interval between 2 platelet transfusion in days	18 month (between 07/01/2015 and 12/31/2016)
Secondary	demographic characteristic	characteristic of patient (age, diagnosis,location of death, palliative care received...)	18 months (between 07/01/2015 and 12/31/2016)